Drug Profile


Alternative Names: 485232; IL-18 - GlaxoSmithKline; Interleukin-18 - GlaxoSmithKline; Recombinant human interleukin-18 - GlaxoSmithKline; rhIL-18; SB-485232

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hayashibara Biochemical Laboratories; Hyogo College of Medicine
  • Developer GlaxoSmithKline
  • Class Antineoplastics; Cytokines
  • Mechanism of Action Interleukin 18 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Non-Hodgkin's lymphoma; Ovarian cancer
  • Discontinued Cancer; Malignant melanoma

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Combination therapy) in USA (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Ovarian-cancer(Combination therapy) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top